Skip to main content

Mudar localização

Você está atualmente no website Brazil (Português)

Meu país não está na lista

Global

  • Bracco.com (English)

Ásia

  • China (中文)
  • Japan (日本語)
  • South Korea (한국어)

Américas

  • Brazil (Português)
  • Canada (English)
  • Mexico (English)
  • Canada (Français)
  • USA (English)

Europa

  • Austria (English)
  • Belgium (English)
  • Czech Republic (English)
  • Denmark (English)
  • Finland (English)
  • France (Français)
  • Germany (Deutsch)
  • Iceland (English)
  • Italy (Italiano)
  • Luxembourg (English)
  • Norway (English)
  • Poland (English)
  • Slovakia (English)
  • Sweden (English)
  • Switzerland (English)
  • The Netherlands (English)
  • UK (English)
  • Carreira
  • Contactar nos
    • Brazil (Português)
  • Página inicial
  • we are bracco
    Nós somos Bracco

    Bem-vindo(a) ao mundo dos meios de contraste

    • Nossos negócios
    • Passado, presente, futuro
    • A Fundação
    • Responsabilidade
  • Nosso portfólio

    Oferta comprovada para uma diferença comprovada

    • Raio-X & TC
      • Contrast agents

        • Iopamiron
        • Iomeron
      • Medical devices

        • Empower CTA
        • Empower CTA+
    • RM
      • Contrast agents

        • MultiHance
        • ProHance
      • Medical Devices

        • Empower MR
    • Ultrassom
      • Contrast agents

        • SonoVue
    • Medicina Nuclear
    • Cardiologia intervencionista
      • Contrast agents

        • Iomeron
      • Medical devices

        • ACIST CVi
    • Soluções digitais
    • Oncologia
    • Cardiologia
  • Woman looking into microscope
    Inovação

    Um profundo mergulho em nosso progresso de P&D

    • Futuro digital
    • P&D
    • Os sites Bracco
    • Patrimônio científico e patentes
  • knowledge
    Conhecimento

    O que sabemos e compartilhamos

    • E-learning
    • Parcerias em educação
    • Eventos
  • sustainability
    Sustentabilidade

    Nosso plano e objetivo para um mundo melhor

    • Nossos pilares de sustentabilidade
    • Governança
    • Nosso relatório de sustentabilidade
  • Nossas histórias
Article
Bracco Suisse and Verasonics: a new strategic partnership The collaboration focuses on combining Verasonics' Vantage®️ NXT Research Ultrasound Systems with Bracco's contrast agents to explore improved imaging performance in various research applications.
Verasonics logo
Article
Blue Earth Diagnostics appoints Marco Campione as Chief Executive Officer Mr. Campione brings more than 25 years global experience in successful development and commercialization of diagnostic imaging agents and radiopharmaceuticals.
Blue Earth Diagnostic
Article
Bracco Imaging and Arrayus Technologies: a new strategic partnership Bracco Imaging and Arrayus Technologies have partnered to improve drug delivery for pancreatic cancer using focused ultrasound and microbubble technology.
Bracco Arrayus partnership
Article
AI Pills in Medical Writing This webinar series, in collaboration with Springer Healthcare Italia, a global leader in healthcare education and communication, is designed to provide radiologists with practical insights into the use of innovative digital tools and technologies to improve the effectiveness of medical writing.
AI Pills in Medical Writing
Article
Gadopiclenol receives the JFR 2024 Innovation Award Bracco Imaging is delighted to announce that Gadopiclenol (marketed as Vueway® by Bracco) has been honored with the JFR 2024 Innovation Award in the Jury's Favorite category.
Prix Innovation Award JFR 2024
Article
Bracco Diagnostics and Subtle Medical Announce FDA Clearance of AiMIFY™ Software Bracco Diagnostics Inc. and Subtle Medical, Inc. are thrilled to announce that their collaborative AI-powered software, AiMIFYTM, has received FDA clearance as a Class II software as a medical device (SaMD) for magnetic resonance imaging (MRI) of the brain.
BRACCO IMAGING S.p.A. ANNOUNCES GLOBAL AGREEMENT WITH SUBTLE MEDICAL, Inc.
Article
Bracco triples production of its innovative ultrasound contrast agent in Geneva Over 80 million euros has been invested to build Hexagon, a new manufacturing facility located next to the historical 1996 plant which will, when fully operational, triple the production and distribution of one of the leading products from Bracco's research.
Bracco production innovative ultrasound contrast agent Geneva
Article
EuSoMII and Bracco together for the 2nd AI Contest One year is gone and we are back in Pisa. It’s the 10th (and 11th) of October 2024, and the EuSoMII, is hosting its annual meeting that brings together people with different backgrounds and expertise from the world of radiology. 
EuSoMII/Bracco AI Contest at the EuSoMII Annual Meeting in Pisa
Article
Webinar: Effective Gadolinium Reduction with the New High- Relaxivity Gadopiclenol in CNS We are pleased to invite you to join an educational webinar entitled Effective Gadolinium Reduction with the New High- Relaxivity Gadopiclenol in CNS scheduled for January 15 from 6:00 to 7:00 pm CET.
Bracco Vueway
Article
Bracco and Aenitis Partner on Acoustic Beads for Cell Sorting This strategic partnership is set to explore the development of next-generation acoustic microspheres, a groundbreaking alternative to conventional magnetic beads for rare and complex cell sorting and separation in flow-based applications.
Aenitis Technologies
  • Load More

O Grupo Bracco é um grupo internacional de empresas altamente especializadas.
Somos uma parte ativa do setor de saúde e líder global em diagnóstico por imagem.

  • Nós somos Bracco
  • Nosso portfólio
  • Inovação
  • Conhecimento
  • Sustentabilidade
  • Nossas histórias
  • Farmacovigilância
  • Data Protection

Siga-nos

Bracco Imaging do Brasil
Endereço Matriz:
AV. OL 3, 200 Duque de Caxias
Rio de Janeiro, CEP: 25085-375
Tel: 55 21 2772 1919
Escritório São Paulo
Rua Samuel Morse, 120 cj. 151/152
Cid. Monções, São Paulo-SP, CEP: 04576-060
Tel: 55 11 2181 2100
SAC: 0800 710
2100

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Imprint
  • for Bracco VPN users

Bracco Copyright © 2025 | Registered office: Via E. Folli, 50, 20134 Milano, Italy | Share Capital € 104.000.000 f.p. | VAT Milan Comp. Reg. n. 00825120157 | Milan REA n. 348182